Skip to main content

Insight into p95HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies

Buy Article:

$113.00 plus tax (Refund Policy)


Breast cancer afflicts more than 1.3 million people worldwide and is the main cause of cancer-related deaths among women. Many efforts are underway to develop new therapeutic and biomarker strategies for the management of this disease. Hormone receptors and human epidermal growth factor receptor 2 (HER2) are currently the most important molecular tools in this regard. Moreover, targeted therapies including trastuzumab in particular are the primary treatment in both the adjuvant and recurrent settings. However, many studies reported that selected patients may present with resistance to trastuzumab due to the presence of p95HER2 fragments. To address this challenge, drugs such as lapatinib and others described in recent patents promise alternative therapeutic options. We discuss the most recent patents related to HER2 and p95HER2 fragments for breast cancer treatment.

Keywords: ANTI-HER2 DRUG RESISTANCE; Monoclonal antibodies; Neratinib; T-DM1; biomarkers; breast neoplasms; erbB-2; genes; human HER2 protein; lapatinib; neratinib; p95HER2; pertuzumab; pharmacogenetics; rastuzumab; trastuzumab-DM1

Document Type: Research Article


Publication date: April 1, 2012

More about this publication?
  • Recent Patents on DNA and Gene Sequences publishes review articles by experts on recent patents on DNA and gene sequences. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in applied molecular biology.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more